129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

• Status: Not yet recruiting
• Trial end date: 2026-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bastiaan Driehuys
• Collaborator: American Heart Association

Criteria

Inclusion Criteria:

Arm 1 -IPAH

• Age: 18-75 years

• WHO functional class 2 or 3

• Mean pulmonary artery pressures > 20 mmHg

• Pulmonary capillary wedge pressure ≤15 mmHg

• Pulmonary vascular resistance > 2 Wood Units (WU)

• No other cause identified for PAH

Arm 2 -PAH-CTD

• Age: 18-75 years

• WHO functional class (FC) 2 or 3

• Mean pulmonary artery pressures > 20 mmHg

• Pulmonary capillary wedge pressure ≤15 mmHg

• Pulmonary vascular resistance > 2 WU

• Diagnosis of connective tissue disease

Exclusion Criteria:

• PH other than Idiopathic PAH or PAH associated with CTD; any conditions that prevent the performance of 129Xe MRI scans will be excluded from the study.